August 28, 2014 11:12 AM ET


Company Overview of Visterra, Inc.

Company Overview

Visterra, Inc. operates as a biotechnology company. It uses its atomic interaction network analysis to identify disease targets and design therapeutics. The company focuses on therapeutics for infectious diseases and its antibody product candidate, VIS410, a human monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza. It also develops dengue antibody programs; and has a drug development program for an antibody to treat four strains of dengue virus. In addition, it focuses on research programs for infectious and non-infectious diseases; and other collaborative programs. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Vi...

One Kendall Square

Suite B3301

Cambridge, MA 02139

United States

Founded in 2007





Key Executives for Visterra, Inc.

Chief Executive Officer
Age: 55
Founder and Director
Age: 49
Chief Financial Officer and Chief Operating Officer
Age: 53
Chief Medical Officer
Vice President of Legal
Compensation as of Fiscal Year 2014.

Visterra, Inc. Key Developments

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.

Visterra Inc. Acquires Exclusive Patent License for Monoclonal Antibodies Against Dengue Virus from Massachusetts Institute of Technology

Visterra Inc. announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

Visterra, Inc. Announces Management Changes

Visterra, Inc. announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, David Arkowitz has joined the company as Chief Operating Officer and Chief Financial Officer, and Greg Miller will serve as Vice President of Business Development and Strategic Planning. Most recently, Mr. Arkowitz was at Mascoma Corporation, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Prior to joining Mascoma, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals. Most recently, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals since 2010. Prior to that, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals from 2008 to 2010.

Similar Private Companies By Industry

Company Name Region
Meridian Life Science, Inc. United States
Firefly BioWorks, Inc. United States
Cytoprint Inc. United States
Medicore, Inc. United States
Corvas International, Inc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Visterra, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at